Voluntis on receiving FDA 510(K) Clearance and expanding

Voluntis’ flagship diabetes digital therapeutic, Insulia, helps people with type 2 diabetes with dose titration. It is indicated for patients with type 2 diabetes initiating or uncontrolled on basal insulin, treated with a wide range of basal insulin analogues, including all approved insulin glargine.

Voluntis has integrated this new product version within the scope of its CE mark for Insulia.

Insulia® provides automated insulin dose recommendations and coaching messages for people with type 2 diabetes while enabling the health care team to remotely monitor progress.

Link to their press release.